Celiac DiseaseNCT07815821
Effects of A2 Dairy Consumption in Celiac Adolescents
A study testing A2 β-casein milk and dairy products and Standard milk and dairy products in people with Celiac Disease and Celiac Disease in Children, run by Halic University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this clinical trial is to evaluate the effect of A2 β-casein-containing milk and dairy product consumption on nutritional status, gastrointestinal symptoms, quality of life, sleep quality, and selected biochemical parameters in adolescents aged 10-18 years with celiac disease. Read more about this study
- Who is it for?
- Ages 10 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Celiac Disease, Celiac Disease in Children, A2 β-casein-containing Milk and Dairy Products
- What is being tested?
- A2 β-casein milk and dairy products and Standard milk and dairy products
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2024to 3 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Adolescents aged 10-18 years
- Diagnosis of celiac disease according to ESPGHAN criteria
- Being diagnosed with celiac disease within the last 3 months
- Volunteering to participate in the study
Who cannot join
- Presence of any chronic disease other than celiac disease
- Presence of lactose intolerance
- Presence of cow's milk protein allergy
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Sariyer Hamidiye Etfal Training and Research Hospital
Istanbul, 34421
About this study
Official title: Evaluation of the Effects of Consumption of Milk and Dairy Products Containing A2 β-Casein on Nutritional Status, Quality of Life, and Certain Blood Parameters in Adolescents With Celiac Disease
The goal of this clinical trial is to evaluate the effect of A2 β-casein-containing milk and dairy product consumption on nutritional status, gastrointestinal symptoms, quality of life, sleep quality, and selected biochemical parameters in adolescents aged 10-18 years with celiac disease.
The main questions it aims to answer are:
Read more
- Does consumption of A2 β-casein-containing milk and dairy products improve gastrointestinal symptoms and quality of life in adolescents with celiac disease?
- Does consumption of A2 β-casein-containing milk and dairy products affect nutritional status, body composition, and biochemical parameters compared with standard milk and dairy products?
Researchers will compare adolescents consuming A2 β-casein-containing milk and dairy products with adolescents consuming standard milk and dairy products to see if A2 β-casein provides additional benefits.
Participants will:
- Consume the assigned milk and dairy products during the intervention period.
- Attend baseline and follow-up assessments.
- Complete dietary records and questionnaires related to gastrointestinal symptoms, sleep quality, and quality of life.
- Undergo anthropometric, body composition, hand grip strength, and biochemical assessments.
- Conditions
- Celiac Disease, Celiac Disease in Children, A2 β-casein-containing Milk and Dairy Products
- Being tested
- A2 β-casein milk and dairy products, Standard milk and dairy products
- Medical subject headings
- Celiac Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A2 β-casein milk and dairy productsDietary supplement
Participants consumed milk and dairy products containing A2 β-casein during the 8-week intervention period.
Standard milk and dairy productsDietary supplement
Participants consumed standard milk and dairy products during the 8-week intervention period.
| Study group | Role | What they receive |
|---|---|---|
| A2 β-casein-containing milk and dairy products | Experimental | Participants assigned to this group consumed milk and dairy products containing A2 β-casein during the intervention period. Receives: Dietary Supplement: A2 β-casein milk and dairy products |
| Standard milk and dairy products group | Active comparator | Participants assigned to this group consumed standard milk and dairy products containing conventional β-casein during the intervention period. Receives: Dietary Supplement: Standard milk and dairy products |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Celiac Disease-Specific Quality of Life Total Score at Week 8
Celiac disease-specific quality of life will be assessed using the Celiac Disease Dutch Questionnaire (CDDUX). The total score ranges from 0 to 100, with higher scores indicating better quality of life.
Measured: Baseline and Week 8
Change From Baseline in Celiac Symptom Index Total Score at Week 8
Gastrointestinal symptoms will be assessed using the Celiac Symptom Index (CSI). The CSI total score ranges from 16 to 80, with higher scores indicating more severe celiac disease-related symptoms.
Measured: Baseline and 8 weeks
Change From Baseline in Anti-tTG IgA Level at Week 8
Serum anti-tissue transglutaminase immunoglobulin A (anti-tTG IgA) level will be measured and reported as RU/mL to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Anti-tTG IgG Level at Week 8
Serum anti-tissue transglutaminase immunoglobulin G (anti-tTG IgG) level will be measured and reported as RU/mL to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Leukocyte Count at Week 8
Leukocyte count will be measured in blood samples and reported as 10⁹/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Neutrophil Count at Week 8
Absolute neutrophil count will be measured in blood samples and reported as 10⁹/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Neutrophil-to-Lymphocyte Ratio at Week 8
The neutrophil-to-lymphocyte ratio (NLR) will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. NLR will be reported as a unitless ratio to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Albumin Level at Week 8
Serum albumin level will be measured and reported as g/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Total Protein Level at Week 8
Serum total protein level will be measured and reported as g/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Alanine Aminotransferase Level at Week 8
Serum alanine aminotransferase (ALT) level will be measured and reported as U/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Aspartate Aminotransferase Level at Week 8
Serum aspartate aminotransferase (AST) level will be measured and reported as U/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Ferritin Level at Week 8
Serum ferritin level will be measured and reported as µg/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Folate Level at Week 8
Serum folate level will be measured and reported as µg/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Vitamin B12 Level at Week 8
Serum vitamin B12 level will be measured and reported as ng/L to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Serum Calcium Level at Week 8
Serum calcium level will be measured and reported as mg/dL to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Body Weight at Week 8
Body weight will be measured and reported in kilograms (kg) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Height at Week 8
Height will be measured and reported in centimeters (cm) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in BMI-for-Age Z Score at Week 8
BMI-for-age Z score will be calculated using the World Health Organization 2007 growth reference for children and adolescents aged 5-19 years to assess the change from baseline to Week 8. A score of 0 represents the median of the reference population.
Measured: Baseline and Week 8
Change From Baseline in Mid-Upper Arm Circumference at Week 8
Mid-upper arm circumference (MUAC) will be measured and reported in centimeters (cm) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Body Mass Index at Week 8
Body mass index (BMI) will be calculated by dividing body weight in kilograms by height in meters squared and reported as kg/m² to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Height-for-Age Z Score at Week 8
Height-for-age Z score will be calculated using the World Health Organization 2007 growth reference for children and adolescents aged 5-19 years to assess the change from baseline to Week 8. A score of 0 represents the median of the reference population.
Measured: Baseline and Week 8
Change in Sleep Quality Assessed by the Pittsburgh Sleep Quality Index (PSQI)
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI total score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Measured: Baseline and Week 8
Change in Hand Grip Strength Measured Using a TAKEI TKK-5401 Hand Dynamometer
Hand grip strength (kg) will be measured using a TAKEI TKK-5401 hand dynamometer.
Measured: Baseline and Week 8
Change in Stool Form Assessed by the Bristol Stool Form Scale (BSFS)
Stool form will be assessed using the Bristol Stool Form Scale (BSFS). The scale classifies stool form into seven types (Types 1-7), with Types 1-2 indicating constipation, Types 3-4 indicating normal stool form, and Types 5-7 indicating loose stools or diarrhea.
Measured: Baseline and Week 8
Change From Baseline in Trunk Fat Percentage at Week 8
Trunk fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Total Body Fat Percentage at Week 8
Total body fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Right Arm Fat Percentage at Week 8
Right arm fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Left Arm Fat Percentage at Week 8
Left arm fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Right Leg Fat Percentage at Week 8
Right leg fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Left Leg Fat Percentage at Week 8
Left leg fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Body Fat Mass at Week 8
Body fat mass will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported in grams (g) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Change From Baseline in Fat-Free Mass at Week 8
Fat-free mass will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported in grams (g) to assess the change from baseline to Week 8.
Measured: Baseline and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start1 Feb 2024
- Primary completion1 Jun 2026
- Study completion3 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Celiac DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Halic University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07815821
- Sponsor's protocol ID
- 125S700
- Status last verified
- Oct 2026
- First submitted
- 23 Jul 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effects of Consumption of Milk and Dairy Products Containing A2 β-Casein on Nutritional Status, Quality of Life, and Certain Blood Parameters in Adolescents With Celiac Disease
- ClinicalTrials.gov ID
- NCT07815821
- Acronym / sponsor ID
- 125S700
- Conditions
- Celiac Disease, Celiac Disease in Children, A2 β-casein-containing Milk and Dairy Products
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Halic UniversityUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 3 Jul 2026 (actual)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the effect of A2 β-casein-containing milk and dairy product consumption on nutritional status, gastrointestinal symptoms, quality of life, sleep quality, and selected biochemical parameters in adolescents aged 10-18 years with celiac disease.
The main questions it aims to answer are:
- Does consumption of A2 β-casein-containing milk and dairy products improve gastrointestinal symptoms and quality of life in adolescents with celiac disease?
- Does consumption of A2 β-casein-containing milk and dairy products affect nutritional status, body composition, and biochemical parameters compared with standard milk and dairy products?
Researchers will compare adolescents consuming A2 β-casein-containing milk and dairy products with adolescents consuming standard milk and dairy products to see if A2 β-casein provides additional benefits.
Participants will:
- Consume the assigned milk and dairy products during the intervention period.
- Attend baseline and follow-up assessments.
- Complete dietary records and questionnaires related to gastrointestinal symptoms, sleep quality, and quality of life.
- Undergo anthropometric, body composition, hand grip strength, and biochemical assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A2 β-casein-containing milk and dairy products | Experimental | Dietary Supplement: A2 β-casein milk and dairy productsParticipants assigned to this group consumed milk and dairy products containing A2 β-casein during the intervention period. |
| Standard milk and dairy products group | Active comparator | Dietary Supplement: Standard milk and dairy productsParticipants assigned to this group consumed standard milk and dairy products containing conventional β-casein during the intervention period. |
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Adolescents aged 10-18 years
- Diagnosis of celiac disease according to ESPGHAN criteria
- Being diagnosed with celiac disease within the last 3 months
- Volunteering to participate in the study
Key exclusion criteria (3 listed)
- Presence of any chronic disease other than celiac disease
- Presence of lactose intolerance
- Presence of cow's milk protein allergy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A2 β-casein milk and dairy productsParticipants consumed milk and dairy products containing A2 β-casein during the 8-week intervention period. | Dietary supplement | A2 β-casein-containing milk and dairy products |
| Standard milk and dairy productsParticipants consumed standard milk and dairy products during the 8-week intervention period. | Dietary supplement | Standard milk and dairy products group |
Primary outcome
Change From Baseline in Celiac Disease-Specific Quality of Life Total Score at Week 8
Time frame: Baseline and Week 8
Celiac disease-specific quality of life will be assessed using the Celiac Disease Dutch Questionnaire (CDDUX). The total score ranges from 0 to 100, with higher scores indicating better quality of life.
Change From Baseline in Celiac Symptom Index Total Score at Week 8
Time frame: Baseline and 8 weeks
Gastrointestinal symptoms will be assessed using the Celiac Symptom Index (CSI). The CSI total score ranges from 16 to 80, with higher scores indicating more severe celiac disease-related symptoms.
Change From Baseline in Anti-tTG IgA Level at Week 8
Time frame: Baseline and Week 8
Serum anti-tissue transglutaminase immunoglobulin A (anti-tTG IgA) level will be measured and reported as RU/mL to assess the change from baseline to Week 8.
Change From Baseline in Anti-tTG IgG Level at Week 8
Time frame: Baseline and Week 8
Serum anti-tissue transglutaminase immunoglobulin G (anti-tTG IgG) level will be measured and reported as RU/mL to assess the change from baseline to Week 8.
Change From Baseline in Leukocyte Count at Week 8
Time frame: Baseline and Week 8
Leukocyte count will be measured in blood samples and reported as 10⁹/L to assess the change from baseline to Week 8.
Change From Baseline in Neutrophil Count at Week 8
Time frame: Baseline and Week 8
Absolute neutrophil count will be measured in blood samples and reported as 10⁹/L to assess the change from baseline to Week 8.
Change From Baseline in Neutrophil-to-Lymphocyte Ratio at Week 8
Time frame: Baseline and Week 8
The neutrophil-to-lymphocyte ratio (NLR) will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. NLR will be reported as a unitless ratio to assess the change from baseline to Week 8.
Change From Baseline in Serum Albumin Level at Week 8
Time frame: Baseline and Week 8
Serum albumin level will be measured and reported as g/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Total Protein Level at Week 8
Time frame: Baseline and Week 8
Serum total protein level will be measured and reported as g/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Alanine Aminotransferase Level at Week 8
Time frame: Baseline and Week 8
Serum alanine aminotransferase (ALT) level will be measured and reported as U/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Aspartate Aminotransferase Level at Week 8
Time frame: Baseline and Week 8
Serum aspartate aminotransferase (AST) level will be measured and reported as U/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Ferritin Level at Week 8
Time frame: Baseline and Week 8
Serum ferritin level will be measured and reported as µg/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Folate Level at Week 8
Time frame: Baseline and Week 8
Serum folate level will be measured and reported as µg/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Vitamin B12 Level at Week 8
Time frame: Baseline and Week 8
Serum vitamin B12 level will be measured and reported as ng/L to assess the change from baseline to Week 8.
Change From Baseline in Serum Calcium Level at Week 8
Time frame: Baseline and Week 8
Serum calcium level will be measured and reported as mg/dL to assess the change from baseline to Week 8.
Change From Baseline in Body Weight at Week 8
Time frame: Baseline and Week 8
Body weight will be measured and reported in kilograms (kg) to assess the change from baseline to Week 8.
Change From Baseline in Height at Week 8
Time frame: Baseline and Week 8
Height will be measured and reported in centimeters (cm) to assess the change from baseline to Week 8.
Change From Baseline in BMI-for-Age Z Score at Week 8
Time frame: Baseline and Week 8
BMI-for-age Z score will be calculated using the World Health Organization 2007 growth reference for children and adolescents aged 5-19 years to assess the change from baseline to Week 8. A score of 0 represents the median of the reference population.
Change From Baseline in Mid-Upper Arm Circumference at Week 8
Time frame: Baseline and Week 8
Mid-upper arm circumference (MUAC) will be measured and reported in centimeters (cm) to assess the change from baseline to Week 8.
Change From Baseline in Body Mass Index at Week 8
Time frame: Baseline and Week 8
Body mass index (BMI) will be calculated by dividing body weight in kilograms by height in meters squared and reported as kg/m² to assess the change from baseline to Week 8.
Change From Baseline in Height-for-Age Z Score at Week 8
Time frame: Baseline and Week 8
Height-for-age Z score will be calculated using the World Health Organization 2007 growth reference for children and adolescents aged 5-19 years to assess the change from baseline to Week 8. A score of 0 represents the median of the reference population.
Change in Sleep Quality Assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline and Week 8
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI total score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Change in Hand Grip Strength Measured Using a TAKEI TKK-5401 Hand Dynamometer
Time frame: Baseline and Week 8
Hand grip strength (kg) will be measured using a TAKEI TKK-5401 hand dynamometer.
Change in Stool Form Assessed by the Bristol Stool Form Scale (BSFS)
Time frame: Baseline and Week 8
Stool form will be assessed using the Bristol Stool Form Scale (BSFS). The scale classifies stool form into seven types (Types 1-7), with Types 1-2 indicating constipation, Types 3-4 indicating normal stool form, and Types 5-7 indicating loose stools or diarrhea.
Change From Baseline in Trunk Fat Percentage at Week 8
Time frame: Baseline and Week 8
Trunk fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Total Body Fat Percentage at Week 8
Time frame: Baseline and Week 8
Total body fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Right Arm Fat Percentage at Week 8
Time frame: Baseline and Week 8
Right arm fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Left Arm Fat Percentage at Week 8
Time frame: Baseline and Week 8
Left arm fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Right Leg Fat Percentage at Week 8
Time frame: Baseline and Week 8
Right leg fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Left Leg Fat Percentage at Week 8
Time frame: Baseline and Week 8
Left leg fat percentage will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported as a percentage (%) to assess the change from baseline to Week 8.
Change From Baseline in Body Fat Mass at Week 8
Time frame: Baseline and Week 8
Body fat mass will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported in grams (g) to assess the change from baseline to Week 8.
Change From Baseline in Fat-Free Mass at Week 8
Time frame: Baseline and Week 8
Fat-free mass will be assessed using bioelectrical impedance analysis (Tanita BC-601) and reported in grams (g) to assess the change from baseline to Week 8.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Related trials for Celiac Disease
Active, not recruitingEarly Phase 1
VTP-1000 in Adults With Celiac Disease
Celiac Disease
RecruitingObservational study
Impact of Mediterranean Diet and Processed Food Consumption on Gastrointestinal Symptoms in Coeliac Patients on a Gluten-Free Diet
Celiac Disease, Gluten-free Diet
Recruiting
GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)
Celiac Disease in Children, Nutrition Disorder, Child
RecruitingObservational study
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
Celiac Disease
RecruitingObservational study
Pathogenic Study of Adult Immune Enteropathies
Celiac Disease, Autoimmune Enteropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing A2 β-casein milk and dairy products and Standard milk and dairy products in people with Celiac Disease and Celiac Disease in Children, run by Halic University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Celiac Disease-Specific Quality of Life Total Score at Week 8 (time frame: Baseline and Week 8). The study lists 32 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.